These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25968836)

  • 1. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
    Portman DJ; Labrie F; Archer DF; Bouchard C; Cusan L; Girard G; Ayotte N; Koltun W; Blouin F; Young D; Wade A; Martel C; Dubé R;
    Menopause; 2015 Dec; 22(12):1289-95. PubMed ID: 25968836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C; Labrie F; Archer DF; Ke Y; Gonthier R; Simard JN; Lavoie L; Vaillancourt M; Montesino M; Balser J; Moyneur É;
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
    J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Science of intracrinology in postmenopausal women.
    Labrie F; Bélanger A; Pelletier G; Martel C; Archer DF; Utian WH
    Menopause; 2017 Jun; 24(6):702-712. PubMed ID: 28098598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
    Ke Y; Labrie F; Gonthier R; Simard JN; Bergeron D; Martel C; Vaillancourt M; Montesino M; Lavoie L; Archer DF; Balser J; Moyneur E;
    J Steroid Biochem Mol Biol; 2015 Nov; 154():186-96. PubMed ID: 26291918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Bérubé R; Bélanger P; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):897-906. PubMed ID: 19436226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
    Labrie F; Martel C; Bérubé R; Côté I; Labrie C; Cusan L; Gomez JL
    J Steroid Biochem Mol Biol; 2013 Nov; 138():359-67. PubMed ID: 23954500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.
    Labrie F
    J Steroid Biochem Mol Biol; 2015 Jan; 145():133-8. PubMed ID: 24923731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Gilbert L; Martel C; Balser J
    J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
    Panjari M; Davis SR
    Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women.
    Labrie F; Diamond P; Cusan L; Gomez JL; Bélanger A; Candas B
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3498-505. PubMed ID: 9329392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.
    Labrie F; Martel C
    Horm Mol Biol Clin Investig; 2017 Feb; 29(2):39-60. PubMed ID: 27997350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA.
    Ke Y; Gonthier R; Simard JN; Archer D; Lavoie L; Martel C; Vaillancourt M; Labrie F
    Horm Mol Biol Clin Investig; 2015 Dec; 24(3):117-29. PubMed ID: 26509785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
    Bouchard C; Labrie F; Derogatis L; Girard G; Ayotte N; Gallagher J; Cusan L; Archer DF; Portman D; Lavoie L; Beauregard A; Côté I; Martel C; Vaillancourt M; Balser J; Moyneur E;
    Horm Mol Biol Clin Investig; 2016 Mar; 25(3):181-90. PubMed ID: 26725467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
    Archer DF; Labrie F; Montesino M; Martel C
    J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
    Labrie F; Montesino M; Archer DF; Lavoie L; Beauregard A; Côté I; Martel C; Vaillancourt M; Balser J; Moyneur E;
    Climacteric; 2015; 18(6):817-25. PubMed ID: 26517756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.